Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
|Videos|March 17, 2021
Refining Combination Strategies in Metastatic RCC
Author(s)Toni K. Choueiri, MD, Robert J. Motzer, MD
Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Acting on a HER2 Result and Navigating Access to Therapy
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5